What drove the significant increase in revenue for HCA Healthcare in the second quarter of 2024?

The revenue growth was primarily driven by a 10.3% increase on a consolidated basis, attributed to a 4.1% rise in revenue per equivalent admission and a 6.0% increase in equivalent admissions. This indicates both higher patient service prices and increased patient volumes.

Why did cash flow from operating activities decline despite strong revenue and net income growth?

The decline in operating cash flow is mainly due to unfavorable changes in working capital by $824 million, specifically an increase in accounts receivable and a decrease in accounts payable. Additionally, income tax payments increased by $232 million compared to the prior year quarter.

What is HCA Healthcare's outlook on expenses, particularly labor and supplies?

HCA Healthcare saw a favorable impact from a 25.7% decline in contract labor costs as a percentage of revenue in Q2 2024. However, overall salaries and benefits per full-time equivalent increased, and other operating expenses, as a percentage of revenue, increased due to higher professional fees and state provider fees, with management expecting continued inflationary pressures.

What is the company's capital allocation strategy, considering its share repurchase program and dividend?

HCA Healthcare continues to actively return capital to shareholders through share repurchases and dividends. In Q2 2024, it repurchased 4.217 million shares and paid dividends. The company has a substantial $4.228 billion remaining authorization for share repurchases, indicating a commitment to reducing share count and enhancing shareholder value.

HCA 10-Q Quarterly Report Q2 FY2024 — Revenue, Net Income, EPS

Summary

HCA Healthcare, Inc. (HCA) reported strong financial results for the second quarter of 2024, showcasing significant year-over-year growth in both revenue and net income. Total revenues reached $17.492 billion, a 10.3% increase compared to the same period last year, driven by a healthy rise in revenue per equivalent admission and overall equivalent admissions. Net income attributable to HCA Healthcare, Inc. saw a substantial increase to $1.461 billion, translating to $5.53 per diluted share, up from $1.193 billion or $4.29 per diluted share in Q2 2023. This performance was bolstered by increased patient volumes, with a notable rise in admissions and emergency department visits, while surgeries saw a slight decline. Despite the robust revenue and profit growth, the company experienced a decline in cash flow from operating activities, primarily due to negative changes in working capital and higher income tax payments. However, HCA Healthcare maintained a strategic approach to capital allocation, repurchasing a significant amount of its common stock and continuing its dividend program. The company also highlighted its ongoing investments in capital expenditures, projecting between $5.1 billion and $5.3 billion for 2024, underscoring its commitment to facility improvements and expansion. Management expressed confidence in its ability to meet future liquidity needs through operating cash flows, credit facilities, and access to debt markets, while acknowledging persistent inflationary pressures on operating expenses.

Financial Highlights

46 data points

Beta

Revenue

$17.49B

Net Income

$1.46B

0.1% Net Margin

EPS (Diluted)

$5.53

Total Assets

$57.38B

Cash & Equivalents

$831.00M

Free Cash Flow

$690.00M

Financial Statements

Beta

Revenue	$17.49B
Operating Expenses	$15.26B
Interest Expense	$506.00M
Net Income	$1.46B
EPS (Basic)	$5.60
EPS (Diluted)	$5.53
Shares Outstanding (Basic)	261.16M
Shares Outstanding (Diluted)	264.07M

Key Highlights

1Revenues increased by 10.3% to $17.492 billion in Q2 2024 compared to Q2 2023.
2Net income attributable to HCA Healthcare, Inc. rose to $1.461 billion ($5.53 per diluted share) from $1.193 billion ($4.29 per diluted share) in the prior-year quarter.
3Consolidated admissions increased by 6.0% and same-facility admissions grew by 5.8% year-over-year.
4Revenue per equivalent admission saw a 4.1% increase on a consolidated basis.
5Cash flow from operating activities decreased by $504 million to $1.971 billion, impacted by working capital changes and higher tax payments.
6The company repurchased 4.217 million shares of common stock in Q2 2024 and has $4.228 billion remaining on its repurchase authorization.
7Planned capital expenditures for 2024 are expected to range between $5.1 billion and $5.3 billion.

HCA Healthcare, Inc. Quarterly Report for Q2 Ended Jun 30, 2024

Summary

Financial Highlights

Key Highlights

Frequently Asked Questions